Preparation method of NK cells and use thereof in preparing tumor immunotherapy drugs
Through the M15 polypeptide co-cultured with NK cells, the killing efficiency and IFN-γ secretion level of lung cancer cells were significantly improved, the problem of impaired NK cell function in lung cancer patients was solved, and the effect of tumor immunotherapy was improved.
CN118516306BActive Publication Date: 2025-01-14GUANGZHOU XILING BIOTECHNOLOGY CO LTD
Patent Information
- Application Number
- CN202410619284.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-19
- Publication Date
- 2025-01-14
- Estimated Expiration
- 2044-05-19
AI Technical Summary
Technical Problem
The impaired NK cell function in lung cancer patients leads to poor tumor immunotherapy effects. The existing technology is difficult to effectively improve the activity and anti-tumor effect of NK cells.
Method used
Through the M15 polypeptide (amino acid sequence of MPYSTELIFYIEMDP) co-cultured with NK cells, the tumor killing activity, amplification ability and IFN-γ secretion level of NK cells were significantly enhanced, and apoptosis of tumor cells was promoted.
Benefits of technology
It significantly improves the killing efficiency of NK cells on lung cancer cells, inhibits tumor growth, and improves the purity and anti-tumor activity of NK cells. It is suitable for the preparation of tumor immunotherapy drugs.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN118516306B_ABST
Abstract
The present invention belongs to the field of biomedicine technology. More specifically, it relates to a method for preparing NK cells with high cytotoxic activity and its use in preparing tumor immunotherapy drugs. The present invention first discovered that a polypeptide with an amino acid sequence of MPYSTELIFYIEMDP has the effect of enhancing the cytotoxic activity of NK cells. In a co-culture experiment, the polypeptide showed the effect of promoting NK cell proliferation and increasing the level of IFN-γ secretion of NK cells. It was found in a mouse subcutaneous tumor model that the polypeptide has the effect of significantly inhibiting the growth of mouse subcutaneous tumors, and it is suggested that the polypeptide may exert its anti-tumor activity by promoting the secretion of IFN-γ.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Use of polypeptide in preparation of drug for treating nuclear factor-kB abnormal activation diseases
CN104043102A
Application of Liraglutide in preparing tumor immnuo-therapy drugs
CN111789939A